Sichuan Kelun-Biotech Biopharmaceutical's latest marketcap:
As of 06/18/2025, Sichuan Kelun-Biotech Biopharmaceutical's market capitalization has reached $9.64 B. According to our data, Sichuan Kelun-Biotech Biopharmaceutical is the 1968th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 9.64 B |
| Revenue (ttm) | 261.95 M |
| Net Income (ttm) | -36,149,914.12 |
| Shares Out | 228.54 M |
| EPS (ttm) | -0.16 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 05/19/2025 |
Sichuan Kelun-Biotech Biopharmaceutical's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 06/18/2025 | HK$9.64 B | 103.96% | 1968 |
| 12/31/2024 | HK$37.11 B | 64.54% | 3094 |
| 12/29/2023 | HK$22.56 B | 4398 |
Company Profile
About Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of novel drugs to address unmet medical needs in China and internationally.
Key Focus Areas
- Oncology: Developing treatments for breast, non-small cell lung, and gastrointestinal cancers.
- Non-Oncology: Targeting immune-mediated diseases such as rheumatoid arthritis and alopecia areata.
Product Pipeline
- Oncology Candidates: SKB264 (sacituzumab tirumotecan), A166 (trastuzumab botidotin), SKB315, A167 (tagitanlimab), A140, and A400.
- Non-Oncology Candidates: A223, A277, SKB378, and SKB336.
Collaborations
The company has strategic partnerships with:
- Merck Sharp & Dohme LLC
- Harbour BioMed Therapeutics Limited
- Ellipses Pharma Limited
Corporate Overview
Founded in 2016 and headquartered in Chengdu, China, Sichuan Kelun-Biotech operates as a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
Frequently Asked Questions
-
What is Sichuan Kelun-Biotech Biopharmaceutical's (HKG-6990) current market cap?As of 06/18/2025, Sichuan Kelun-Biotech Biopharmaceutical (including the parent company, if applicable) has an estimated market capitalization of $9.64 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Sichuan Kelun-Biotech Biopharmaceutical (HKG-6990) rank globally by market cap?Sichuan Kelun-Biotech Biopharmaceutical global market capitalization ranking is approximately 1968 as of 06/18/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.